

Financials - Non Lending



Company

HDFC AMC
ABSL AMC
Nippon AMC
UTI AMC
Angel One
BSE

MCX 360 One

Nuvama Wealth

Anand Rathi Wealth

Prudent Corp CAMS

Kfintech

CDSL

Star Health

ICICI Lombard

HDFC Life

ICICI Prudential

SBI Life

Max Financial

Regulations and weak markets to impact performance

Profitability trend to be muted sequentially

- Across segments, the regulatory environment is likely to influence the performance of non-lending financials in 3QFY25. While F&O regulations are anticipated to have an impact on BSE/ANGELONE, new surrender charges will affect LI players. GI players will be impacted by the changes in the reporting of gross premiums for long-term policies.
- Nifty for the quarter was down 8.4%, which will impact AUM growth for AMCs/CAMS/KFin. However, SIP flows have held up strong in Oct'24/Nov'24 at more than INR250b. Yields are likely to be stable given the limited impact of telescopic structure in 3QFY25. Most notably, other income will see a sharp fall due to market correction.
- BSE's premium turnover has been stable despite a sharp decline in notional turnover due to F&O regulations. Additionally, the decline in notional turnover will aid margin expansion as regulatory fees have a direct linkage. On the other hand, ANGELONE's order flow is expected to be weak during the quarter. Lower cash volumes will have an adverse impact on CDSL's transaction charges.
- Wealth managers will incur an MTM hit from the market corrections, which would be partially offset by the inflows. Transaction revenue would also be down sequentially.
- LI players are seeing through the implementation of surrender charges wherein product IRRs and commissions have been altered. VNB margins will be influenced by:

 1) product mix the share of ULIPs remained strong, 2) some benefits of non-par repricing, and 3) the impact of surrender charges. For our coverage universe, we expect a change of -40bp to +70bp sequentially.
- GI players will face an impact from the implementation of the new practice of reporting GWP on a 1/n basis for the long-term business. This will lead to a higher opex ratio, driving up the combined ratio. The health segment's loss ratios will also remain elevated.
- We maintain our high conviction on the capital market plays as highlighted in our recently released thematic report (<u>click here</u>). The current weak trends are transitory and will reset the base for longer-term growth. Our top picks in this space are BSE, ANGELONE, HDFCAMC, and Nuvama.
- Insurance stocks have seen a sharp correction due to media articles on the regulator constraining the role of the bancassurance channel (https://tinyurl.com/4y6zp26k). In such a scenario, we expect LIC and IPRU to outperform, given their lower dependence on the bancassurance channel.

Demat monthly run-rate declines; volumes dip after the new F&O regulations

- Cash ADTO continued its MoM downward trajectory during the first two months of 3QFY25 with declines of 12%/6% MoM in Oct'24/Nov'24. A slight recovery was witnessed in Dec'24 with a 3% MoM growth in cash ADTO.
- In the F&O segment, options volumes witnessed a significant decline after partial implementation of the new F&O regulations in Nov'24, resulting in F&O ADTO dipping 3.5%/14.8%/33.1% in Oct'24/Nov'24/Dec'24.
- BSE's market share in the options segment continues to scale up in terms of notional/ premium turnover, reaching 29%/15% in Dec'24 vs. 27%/13% in Sep'24.
- Incremental demat account additions declined from 4.4m/month in 2QFY25 to 3.5m in Oct'24 and 3.2m in Nov'24. Similarly, incremental NSE active client count has fallen to 1m/0.7m in Oct/Nov '24 from an average of 1.2m in 2QFY25.
- MCX has maintained its momentum with volumes remaining above INR50t in Nov'24/ Dec'24. Futures ADTO increased to INR280b in 3QFY25 from INR270b in

Research Analyst: Prayesh Jain (Prayesh.Jain@MotilalOswal.com) | Nitin Aggarwal (Nitin.Aggarwal@MotilalOswal.com)

Research Analyst: Kartikeya Mohata (Kartikeya.Mohata@MotilalOswal.com) | Muskan Chopra (Muskan.Chopra@MotilalOswal.com)

- 2QFY25. On the other hand, Options ADTO rose to INR2.04t in 3QFY25 from INR1.94t in 2QFY25.
- For BSE, despite an 18% drop in notional ADTO, the premium ADTO for 3QFY25 increased to INR88b from INR82b in 2QFY25. This would drive revenue growth while sequential EBITDA margin expansion of 330bp will be fueled by lower regulatory and clearing & settlement costs.
- We expect ANGELONE to report a revenue decline of 19% QoQ due to a 14% QoQ dip in the number of orders and the impact of true-to-label charges. Lower customer acquisitions, and consequently lower opex, will offset the impact partially.

Mutual Funds: SIP inflows remain strong; equity inflows down from the peak

- Mutual fund AUM grew 43%/40% YoY during Oct'24/Nov'24, driven by 57%/50% growth in equity AUM. While Oct'24 witnessed strong equity inflows of INR587b, a slight slowdown was observed in Nov'24 (INR401b). SIP flows scaled new heights and stood at INR253b for both Oct'24 and Nov'24.
- The AUM of HDFC AMC/Nippon AMC/ABSL AMC/UTI AMC grew 44%/51%/24%/31% YoY at the end of Nov'24, reflecting market shares of 11.5%/8.3%/5.6%/5.2%.
- Equity AUM's share dipped ~70bp in Oct'24 and ~60bp in Nov'24, reaching 57.3%.
- We expect AMCs to register strong revenue growth of 25-38% YoY, propelled by healthy AUM growth. However, their profitability is likely to be hurt by a sharp fall in other income owing to MTM hit on equity exposure in the investment book.
- CAMS and KFin are expected to register healthy revenue growth led by AUM growth and continued momentum in non-MF businesses. Profitability should remain healthy given scale benefits.
- For wealth managers, we expect some hit because of MTM that will be offset by inflows. For 360 One, scaling up in the loan book will also provide support to earnings.

Life Insurance: Mixed performance likely; VNB margin to be stable QoQ

- Private life insurance companies experienced 18%/44% growth in APE in Oct'24/Nov'24. For Dec'24, we expect industry growth momentum to remain stable.
- The industry's VNB margin would be influenced by: 1) product mix share of ULIPs remained strong, 2) some benefits of non-par repricing, and 3) the impact of surrender charges. For our coverage universe, we expect a change of -40bp to +70bp sequentially.

General Insurance: Accounting changes to affect expense ratios

- Excluding crop, the general insurance sector witnessed GWP growth of 20%/3% in Oct'24/ Nov'24. The health segment grew 47%/dipped 1% YoY in Oct'24/Nov'24 (+3% in 2QFY25). Retail health growth was impacted by the change in accounting for long-term policies. The motor segment was hit by low automobile sales and grew 13%/4% YoY in Oct'24/Nov'24 (+6% in 2QFY25).
- For ICICIGI, premium growth in Oct'24/Nov'24 was below the industry average of 3%/-3% YoY. While the retail health segment grew in the high teens, weak motor growth and a decline in the group health segment resulted in a tepid performance.
- For Oct'24/Nov'24, STARHEAL experienced a soft premium growth of 5%/8% YoY, with retail growth of 6%/8% and group health decline of 12%/growth of 2%.

While there is no change in operational efficiency of insurers, the change in accounting for long-term health policies will result in elevated opex ratios. Loss ratios are anticipated to remain elevated, especially in the health segment.


Exhibit 1: Quarterly performance

Castan	CMP	Datina	Dec'24	Variance	Variance	D==/24	Variance	Variance	D==/24	Variance	Variance
Sector	(INR)	Rating	Dec 24	YoY (%)	QoQ (%)	Dec'24	YoY (%)	QoQ (%)	Dec'24	YoY (%)	QoQ (%)
AMC			Operati	ng Revenue	(INR m)	Е	BITDA (INR	m)	N	et Profit (INF	R m)
HDFC AMC	4,162	Buy	9,113	35.7	2.7	7,217	41.1	2.6	6,067	23.9	5.2
ABSL AMC	837	Buy	4,255	24.6	0.3	2,487	28.0	-0.7	2,155	2.9	-11.1
Nippon AMC	754	Buy	5,855	38.3	2.5	3,860	48.9	3.1	3,255	14.6	-9.6
UTI AMC	1,366	Buy	3,776	30.2	1.2	1,825	60.4	-0.2	1,612	-20.7	-38.7
Wealth Manage	ement		Operati	ng Revenue	(INR m)		PBT (INR m)	N	et Profit (INF	R m)
360 One	1,276	Buy	5,678	29.2	-3.5	2,705	30.1	-6.5	2,342	20.7	-5.3
Nuvama	6,974	Buy	7,413	32.8	0.2	3,267	41.8	-6.2	2,430	37.9	-5.8
Anand Rathi	3,935	Neutral	2,522	38.2	4.0	1,094	37.0	5.1	797	37.3	4.5
Prudent	2,726	Neutral	2,922	39.2	2.2	700	40.0	1.9	524	46.7	1.7
Exchanges and	Broking		Operati	ng Revenue	(INR m)	Е	BITDA (INR	m)	N	et Profit (INF	R m)
Angel One	3,017	Buy	8,437	22.7	-13.7	4,287 22.2 -25.1		3,173	21.9	-25.1	
BSE	5,426	Buy	7,589	104.2	1.7	4,204	356.5	8.1	3,690	251.8	6.7
MCX	6,285	Neutral	3,180	66.1	11.4	2,036	NA	13.5	1,728	NA	12.5
Intermediaries			Operati	ng Revenue	(INR m)	E	BITDA (INR	m)	N	et Profit (INF	R m)
CAMS	5,108	Buy	3,725	28.6	2.0	1,744	34.8	2.4	1,255	41.8	3.9
Kfintech	1,545	Neutral	2,945	34.7	5.0	1,352	38.1	6.8	958	43.3	7.2
CDSL	1,809	Neutral	3,086	43.9	-4.2	1,886	43.5	-5.6	1,614	50.1	-0.3
Life Insurance				APE (INR m)		VNB (INR m	1)	N	et Profit (INF	R m)
HDFC Life	617	Buy	38,685	21.2	0.3	9,671	13.0	3.1	4,336	18.8	0.2
IPru Life	661	Buy	25,975	36.2	3.7	5,974	37.0	2.0	2,549	12.0	1.3
SBI Life	1,401	Buy	66,252	8.1	22.9	17,888	6.5	23.4	5,022	56.1	-5.1
Max Financial	1,101	Neutral	20,685	15.2	-4.7	4,861	-0.6	-5.1	1,572	4.1	12.8
General Insurar	nce		Gross	Premium (I	NR m)	Underw	vriting Profi	t (INR m)	N	et Profit (INF	R m)
Star Health	482	Buy	40,385	12.0	-7.6	-564	NA	NA	2,178	-24.8	95.7
ICICI Lombard	1,808	Buy	66,297	3.0	-4.6	-1,609	NA	NA	6,344	47.0	-8.6
Non-Lending			3,28,777	16.8	1.7	74,886	30.9	5.6	53,599	32.0	-3.0

Exhibit 2: Changes to our EPS estimates (*For life insurance companies – absolute VNB in INR b)


6	Nev	w Estimates (I	NR)	Ole	d Estimates (II	NR)		Change (%)	
Company	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E	FY25E	FY26E	FY27E
HDFC AMC	114.1	136.0	154.7	118.9	136.4	155.2	-4.0	-0.3	-0.3
ABSL AMC	32.0	37.3	42.8	34.5	38.2	44.1	-7.0	-2.2	-2.8
Nippon AMC	21.6	26.6	31.2	22.7	26.6	31.2	-4.8	0.0	0.0
UTI AMC	69.1	76.8	87.2	79.8	77.6	88.1	-13.4	-1.0	-1.1
360 One	25.3	34.1	40.3	25.2	33.3	38.4	0.2	2.4	5.0
Nuvama	272.7	314.9	363.2	272.3	314.9	363.2	0.2	0.0	0.0
Anand Rathi	75.3	102.1	122.5	75.3	102.1	122.5	0.0	0.0	0.0
Prudent Corp	49.4	67.1	87.5	49.4	67.1	87.5	0.0	0.0	0.0
Angel One	159.3	169.7	246.8	169.0	189.7	264.1	-5.7	-10.6	-6.5
BSE	98.9	129.0	158.2	99.2	129.0	158.1	-0.3	0.0	0.1
MCX	119.0	166.6	198.8	123.5	166.6	198.8	-3.7	0.0	0.0
CAMS	99.2	119.5	144.0	99.2	119.5	144.0	0.0	0.0	0.0
Kfintech	20.9	26.8	33.8	20.9	26.8	33.8	0.0	0.0	0.0
CDSL	30.1	37.2	46.3	30.7	37.9	47.1	-1.8	-1.8	-1.7
HDFC Life*	40.3	48.5	58.1	39.9	48.0	57.5	0.9	1.0	1.0
ICICI Pru*	25.3	33.9	40.2	26.4	32.1	38.3	-4.0	5.5	4.9
SBI Life*	58.5	71.1	83.3	59.8	72.7	85.2	-2.1	-2.1	-2.1
Max Fin*	20.7	25.7	30.5	21.0	25.7	30.0	-1.5	0.1	1.5
Star Health	13.9	18.4	25.0	17.0	21.3	27.4	-18.0	-13.6	-9.0
ICICI Lombard	50.0	56.6	74.5	50.8	60.6	77.6	-1.6	-6.7	-4.0

Exhibit 3: Total demat accounts surpassed 180m



Source: NSDL, CDSL MOFSL

Exhibit 5: NSE's cash volumes declining since Jul'24




Source: NSE, MOFSL

Exhibit 7: MCX option volumes maintaining momentum




Source: MCX, MOFSL

Exhibit 9: SIP flows continue to achieve new peaks




Source: AMFI, MOFSL

Exhibit 4: BSE's market share in notional turnover improved




Source: NSE, BSE, MOFSL

Exhibit 6: BSE's cash volumes down from the peak




Source: BSE, MOFSL

Exhibit 8: Decline in volumes of MCX futures in Dec'24




Source: MCX, MOFSL

Exhibit 10: Share of equity AUM down from the peak




Source: AMFI, MOFSL

Exhibit 11: Net equity flows declined in Nov'24




Source: AMFI, MOFSL

Exhibit 12: GI premium impacted by accounting change




Source: GIC, MOFSL

Exhibit 13: Motor premium growth trend




Source: GIC, MOFSL

Exhibit 14: Health segment growth trend




Source: GIC, MOFSL

Exhibit 15: Monthly APE for the life insurance industry



Source: Life Insurance Council, MOFSL

Exhibit 16: Individual APE growth YoY for pvt. listed players



Source: Life Insurance Council, MOFSL

The tables below provide a snapshot of the actual and estimated numbers for companies under the MOFSL coverage universe. Highlighted columns indicate the quarter/financial year under review.

ABSL AMC Buy

CMP INR837 | TP: INR1,100 (+31%)

- EPS CHANGE (%): FY25 | 26: -7.0 | -2.2
- Weak market sentiments likely to impact flows into equity schemes; flattish growth in QAAUM expected.
- Expecting yields to remain stable due to flat AUM growth.
- Cost-to-income ratio likely to remain elevated YoY, largely driven by growth in employee expenses.
- Weak market performance during the quarter to hit other income; expected to decline sequentially.

Quarterly Performance										(INR m)
Y/E March		FY2	.4			FY2	.5		EV24	EV2EE
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE	FY24	FY25E
Revenue from Operations	3,112	3,350	3,415	3,656	3,866	4,242	4,255	4,345	13,532	16,708
Change YoY (%)	2.2	7.7	8.7	23.1	24.3	26.6	24.6	18.9	10.3	23.5
Employee Expenses	774	798	794	842	892	894	913	926	3,208	3,625
Total Operating Expenses	1,412	1,431	1,472	1,607	1,664	1,738	1,768	1,789	5,922	6,958
Change YoY (%)	15	11	12	16	18	21	20	11	13.5	17.5
EBITDA	1,700	1,919	1,943	2,049	2,203	2,504	2,487	2,556	7,610	9,750
EBITDA margin (%)	54.6	57.3	56.9	56.0	57.0	59.0	58.5	58.8	56.2	58.4
Other Income	778	557	795	745	948	958	479	614	2,874	2,999
PBT	2,403	2,368	2,635	2,676	3,045	3,351	2,854	3,055	10,082	12,306
Tax Provisions	557	587	542	592	688	928	699	762	2,278	3,076
Net Profit	1,846	1,781	2,093	2,084	2,357	2,423	2,155	2,294	7,804	9,229
Change YoY (%)	79.4	-7.1	25.9	53.7	27.7	36.1	2.9	10.1	30.8	18.3

HDFC AMC

CMP INR4,162 | TP: INR5,200 (+25%)

EPS CHANGE (%): FY25 | 26: -4.0 | -0.3

- Equity AUM to maintain growth momentum backed by improving fund performance.
- Yields likely to decline sequentially but scaling up of AUM to drive revenue growth.
- Consistent cost-to-income ratio with stable growth in operational expenses.
- Weak market performance during the quarter to hurt other income; likely to decline sequentially.

Quarterly Performance										(INR m)
Y/E March		FY	24			FY	25		FY24	FY25E
-	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE		
Revenue from Operations	5,745	6,431	6,713	6,954	7,752	8,872	9,113	9,316	25,843	35,053
Change YoY (%)	10.1	18.1	20.0	28.6	34.9	38.0	35.7	34.0	19.3	35.6
Employee Expenses	838	929	903	864	1,011	959	974	1,003	3,535	3,948
Total Operating Expenses	1,460	1,608	1,599	1,562	1,809	1,838	1,896	1,957	6,229	7,499
Change YoY (%)	10.6	14.7	9.2	19.8	23.9	14.3	18.5	25.3	13.5	20.4
EBIDTA	4,285	4,822	5,114	5,393	5,944	7,034	7,217	7,359	19,615	27,554
EBIDTA Margin (%)	74.6	75.0	76.2	77.5	76.7	79.3	79.2	79.0	75.9	78.6
Other Income	1,580	1,221	1,424	1,555	1,735	1,710	855	1,255	5,781	5,555
PBT	5,713	5,891	6,386	6,791	7,523	8,584	7,910	8,449	24,782	32,466
Tax Provisions	939	1,516	1,489	1,380	1,485	2,818	1,843	1,971	5,323	8,116
Net Profit	4,775	4,376	4,897	5,411	6,038	5,766	6,067	6,479	19,459	24,349
Change YoY (%)	52.0	20.2	32.6	43.8	26.4	31.8	23.9	19.7	36.7	25.1

the quarter.

Nippon Life India AMC

Buv

CMP INR754 | TP: INR900 (+19%)

EPS CHANGE (%): FY25 | 26: -4.8 | 0.0

- Market share in other schemes (ETFs) has been above 17% for the last seven months.
- for the last seven months.

 AUM growth and stable yields to drive revenue growth for
- Scale benefits expected to improve cost-to-income ratio YoY for 3QFY25.
- Significant decline in other income likely due to weak market performance during the quarter.

Quarterly Performance										(INR m)
Y/E March		FY2	24			FY2	5		FY24	FY25E
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE	F124	F123E
Revenue from Operations	3,542	3,975	4,233	4,683	5,050	5,713	5,855	6,013	16,432	22,631
Change YoY (%)	12.0	19.9	19.6	34.4	42.6	43.7	38.3	28.4	21.7	37.7
Employee Expenses	780	799	881	886	1,051	1,069	1,075	1,088	3,346	4,284
Total Operating Expenses	1,517	1,561	1,642	1,775	1,886	1,969	1,995	2,034	6,495	7,884
Change YoY (%)	11	13	17	27	24	26	22	15	17.0	21.4
EBITDA	2,024	2,414	2,592	2,908	3,164	3,744	3,860	3,979	9,937	14,746
EBITDA Margin	57.2	60.7	61.2	62.1	62.7	65.5	65.9	66.2	60.5	65.2
Other Income	1,169	779	1,071	923	1,308	1,208	604	723	3,941	3,843
PBT	3,099	3,104	3,581	3,741	4,388	4,861	4,369	4,601	13,525	18,217
Tax Provisions	746	661	741	315	1,066	1,261	1,114	1,168	2,462	4,609
Net Profit	2,354	2,443	2,840	3,426	3,322	3,600	3,255	3,432	11,063	13,608
Change YoY (%)	105.9	18.6	38.7	73.3	41.1	47.4	14.6	0.2	53.0	23.0

UTI AMC Bu

CMP INR1,366 | TP: INR1,600 (+17%)

EPS CHANGE (%): FY25 | 26: -13.4 | -1.0

- Market share declined across schemes, resulting in marginal
 AUM growth expectation for 3QFY25.
- Yields anticipated to remain broadly stable sequentially, keeping revenue growth flattish QoQ.
- Scale benefits to improve operational efficiency, resulting in YoY improvement in the cost-to-income ratio.
- Significant decline in other income expected due to weak market performance in 3QFY25.

Quarterly Performance										(INR m)
Y/E March		FY2	4			FY2	5		EV24	EVACE
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE	FY24	FY25E
Revenue from Operations	2,828	2,916	2,900	3,177	3,368	3,730	3,776	3,852	11,821	14,725
Change YoY (%)	-1.6	0.3	2.2	17.9	19.1	27.9	30.2	21.3	4.5	24.6
Employee Expenses	1,063	1,112	1,053	1,165	1,137	1,153	1,170	1,197	4,393	4,657
Total Operating Expenses	1,680	1,725	1,762	1,876	1,781	1,901	1,951	2,007	7,043	7,640
Change YoY (%)	11.9	4.6	-0.9	5.0	6.0	10.2	10.7	7.0	4.9	8.5
EBITDA	1,148	1,191	1,138	1,301	1,587	1,829	1,825	1,844	4,778	7,085
EBITDA margin (%)	40.6	40.8	39.2	41.0	47.1	49.0	48.3	47.9	40.4	48.1
Other Income	1,858	1,140	1,602	1,026	1,970	1,671	418	627	5,626	4,685
PBT	2,884	2,198	2,607	2,180	3,413	3,357	2,094	2,318	9,869	11,182
Tax Provisions	540	370	573	365	670	726	482	532	1,848	2,409
Net Profit	2,344	1,828	2,034	1,815	2,743	2,631	1,612	1,787	8,020	8,773
Change YoY (%)	148.3	-9.9	236.5	111.7	17.0	43.9	-20.7	-1.5	80.9	9.4

360ONE WAM Buy

CMP INR1,276 | | TP: INR1,450 (+14%)

EPS CHANGE (%): FY25 | 26: +0.2 | +2.4

- ARR to contribute to overall revenue growth; TBR decline likely to result in sequential dip in revenue.
- Decline in ARR as well as TBR yields to impact overall yields in 3QFY25.
- Cost-to-income ratio is likely to improve YoY due to economies of scale.
 - Performance and costs of new business ventures and entry into new geographies will be closely monitored.

Quarterly Performance										(INR m)
Y/E March		FY2	4			FY2	5E		FY24	FY25E
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE	F124	F123E
Net Revenues	4,055	4,275	4,395	5,731	6,002	5,886	5,678	5,989	18,456	23,555
Change (%)	8.2	11.8	5.9	45.8	48.0	37.7	29.2	4.5	17.9	27.6
ARR Assets Income	3,217	3,108	3,377	3,568	3,756	3,973	4,109	4,458	13,270	16,295
TBR Assets Income	839	1,166	1,018	2,163	2,247	1,913	1,569	1,531	5,185	7,260
Operating Expenses	2,103	2,144	2,315	3,002	2,649	2,992	2,973	3,111	9,565	11,725
Change (%)	25.9	19.5	24.3	62.3	25.9	39.5	28.4	3.6	33.3	22.6
Cost to Income Ratio (%)	51.9	50.2	52.7	52.4	44.1	50.8	52.4	51.9	51.8	49.8
Operating Profits	1,952	2,130	2,080	2,729	3,354	2,893	2,705	2,878	8,891	11,830
Change (%)	-6.0	4.9	-9.0	31.3	71.8	35.8	30.1	5.5	4.9	33.1
Other Income	287	137	271	500	969	298	298	288	1,195	1,852
Profit Before Tax	2,239	2,268	2,350	3,229	4,323	3,191	3,003	3,166	10,085	13,682
Change (%)	11.0	0.5	5.3	61.4	93.1	40.7	27.8	-2.0	18.6	35.7
Tax	2,239	2,268	2,350	3,229	3,447	3,191	3,003	3,166	10,085	12,806
Tax Rate (%)	426	415	410	817	1,011	719	661	621	2,068	3,012
PAT	19.0	18.3	17.4	25.3	23.4	22.5	22.0	19.6	20.5	22.0
Change (%)	1,813	1,853	1,940	2,412	2,435	2,472	2,342	2,544	8,018	9,794
PAT Margins (%)	15.6	6.3	13.1	55.2	34.3	33.4	20.7	5.5	21.8	22.2

Anand Rathi Wealth

Neutral

CMP INR3,935 | | TP: INR4,500 (+14%)

EPS CHANGE (%): FY25 | 26: +0.0 | +0.0

- Consistent AUM growth to be driven by equity and non-PP/SP products.
- Yields to maintain the YoY improvement trajectory and to remain stable sequentially.
- Cost-to-income ratio is likely to improve due to economies of scale and operational efficiency.
- RM addition and productivity improvement will be the key growth drivers.

Quarterly Performance										(INR m)
Y/E March		FY2	24			FY2	!5		EV24	EVALE
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE	FY24	FY25E
MF – Equity & Debt	522	625	715	804	890	1,057	1,099	1,151	2,666	4,197
Distribution of Financial Products	1,215	1,187	1,095	1,024	1,471	1,352	1,406	1,469	4,521	5,698
Other Operating revenue	13	14	14	15	15	15	16	18	56	64
Revenue from Operations	1,750	1,826	1,824	1,843	2,376	2,424	2,522	2,637	7,243	9,959
Change QoQ (%)	22.4	4.3	-0.1	1.0	28.9	2.0	4.0	4.6	32.0	37.5
Operating Expenses	1,016	1,051	1,026	1,111	1,394	1,384	1,428	1,483	4,204	5,688
Change QoQ (%)	24	3	-2	8	25	-1	3	4	36	35
EBIDTA	734	775	798	732	982	1,040	1,094	1,155	3,039	4,271
Depreciation	45	46	50	52	57	61	63	63	194	243
Finance Cost	14	16	16	18	14	30	32	35	65	110
Other Income	34	65	48	129	78	72	77	83	276	310
PBT	709	778	780	790	990	1,021	1,076	1,140	3,057	4,227
Change QoQ (%)	19	10	0	1	25	3	5	6	34	38
Tax Provisions	177	200	200	221	256	259	280	310	798	1,104
Net Profit	533	577	580	569	734	762	797	831	2,259	3,124
Change QoQ (%)	25	8	0	-2	29	4	4	4	34	38

Nuvama Wealth Buy

CMP INR6,974 | | TP: INR8,800 (+26%)

EPS CHANGE (%): FY25 | 26: +0.2 | +0.0

- Wealth and asset management growth expected to remain consistent, offset by decline in capital market income.
- Yields to remain broadly stable sequentially across all business segments.
- Cost-to-income ratio is likely to improve YoY due to economies of scale.
- Expansion strategy and further investment areas to be the key monitorables for future growth.

Quarterly Performance										(INR m)
Y/E March	FY24 FY25							EV24	FV2FF	
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE	FY24	FY25E
Revenue from Operations	4,166	4,924	5,581	5,956	6,675	7,402	7,413	7,759	20,627	29,249
Change YoY (%)	19.2	28.8	38.2	35.5	60.2	50.3	32.8	30.3	30.9	41.8
Employee expenses	2,087	2,119	2,342	2,517	2,793	2,983	3,132	3,259	9,065	12,166
Total Operating Expenses	2,924	3,015	3,277	3,575	3,741	3,920	4,146	4,415	12,791	16,221
Change YoY (%)	8.3	16.1	21.1	25.0	27.9	30.0	26.5	23.5	17.7	26.8
PBT before associate profit share	1,242	1,909	2,304	2,381	2,934	3,482	3,267	3,345	7,836	13,027
Change YoY (%)	56.6	55.7	72.7	55.0	136.2	82.4	41.8	40.5	60.3	66.3
Tax Provisions	317	465	545	564	760	902	849	871	1,891	3,383
PAT before associate profit share	925	1,444	1,759	1,817	2,174	2,580	2,418	2,473	5,945	9,644
Change YoY (%)	70.2	56.8	68.9	55.7	135.0	78.6	37.5	36.1	61.9	62.2
Share of profit of associates	22	5	3	-10	37	0	12	27	20	75
Net Profit	947	1,450	1,762	1,807	2,210	2,580	2,430	2,500	5,964	9,719
Change YoY (%)	73.7	56.5	65.9	57.2	133.5	78.0	37.9	38.4	62.8	63.0
Key Operating Parameters (%)										
Cost to Income Ratio	70.2	61.2	58.7	60.0	56.0	53.0	55.9	56.9	62.0	55.5
PBT Margin	29.8	38.8	41.3	40.0	44.0	47.0	44.1	43.1	38.0	44.5
PAT Margin	22.7	29.4	31.6	30.3	33.1	34.9	32.8	32.2	28.9	33.2

Prudent Corporate Advisory

Neutral EPS CHANGE (%): FY25 | 26: +0.0 | +0.0

CMP INR2,726 | | TP: INR3,200 (+17%)

- Revenue growth to be driven by the sustained growth momentum in AUM, offset by sequential decline in yields.
- Mix of insurance product distribution likely to improve sequentially.
- Cost-to-income ratio is likely to improve YoY due to economies of scale and remain stable sequentially.
- Growth in SIP and market share accretion will be the key growth drivers.

Quarterly Performance (INR m)

Y/E March		FY2	4			FY2	.5		FY24	FY25E
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE	F124	FTZSE
Commission and Fees Income	1,644	1,886	2,084	2,376	2,477	2,845	2,907	3,102	7,990	11,331
Other Operating revenue	10	14	15	21	17	15	15	14	61	62
Revenue from Operations	1,654	1,900	2,099	2,397	2,494	2,861	2,922	3,116	8,051	11,393
Change YoY (%)	28.7	28.7	32.5	35.5	50.8	50.5	39.2	30.0	31.7	41.5
Operating Expenses	1,262	1,469	1,599	1,789	1,904	2,174	2,222	2,362	6,120	8,663
Change YoY (%)	31.1	39.4	38.1	51.0	50.8	48.0	39.0	32.0	40.4	41.6
EBIDTA	392	432	500	608	590	687	700	753	1,932	2,730
Depreciation	59.6	61.3	63.0	64.3	62.9	67.2	67.2	67.7	248	265
Finance Cost	6.0	5.0	3.6	7.8	4.9	5.7	5.7	7.7	21	24
Other Income	49	41	45	62	70	78	70	70	196	288
PBT	375	406	479	598	592	693	697	747	1,858	2,729
Change YoY (%)	34.1	9.6	24.4	5.6	57.9	70.6	45.7	25.1	18.5	46.9
Tax Provisions	95.5	101.7	121.6	152.1	149.9	177.9	173.6	180.8	471	682
Net Profit	279	304	357	446	442	515	524	567	1,387	2,047
Change YoY (%)	31.4	10.0	25.1	4.6	58.3	69.2	46.7	27.2	18.9	47.5

Angel One Buy

CMP INR3,017 | TP: INR3,800 (+26%)

commodity volumes remain strong.

EPS CHANGE (%): FY25 | 26: -5.7 | -10.6

- lowest since Jul'23.
- Slowdown in daily order run-rate and F&O/cash volumes;
- Pace of client addition has moderated in Nov'24 and was the MTF book expanded at a strong pace and has been stable over the last three months.
 - Weak client acquisitions, offset by increased hiring costs, to improve the cost-to-income ratio YoY.

Quarterly Performance										(INR m)
Y/E March		FY	24			FY2	5E		FY24	FY25E
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE	F124	F1Z3E
Revenue from Operations	5,198	6,747	6,874	8,742	9,150	9,774	8,437	8,942	27,562	36,304
Other Income	1,088	1,411	1,401	1,869	1,983	2,210	1,216	1,292	5,769	6,700
Total Income	6,286	8,158	8,275	10,611	11,133	11,984	9,653	10,234	33,331	43,004
Change YoY (%)	22.0	46.0	43.9	64.7	77.1	46.9	16.6	-3.6	45.3	29.0
Operating Expenses	3,230	3,974	4,635	5,856	6,940	6,007	5,080	6,043	17,695	24,069
Change YoY (%)	21.4	49.3	75.1	114.0	114.8	51.2	9.6	3.2	65.3	36.0
Depreciation	89	112	131	167	226	256	286	316	498	1,084
PBT	2,967	4,072	3,509	4,588	3,968	5,721	4,287	3,875	15,137	17,851
Change YoY (%)	22.3	42.5	16.1	26.9	33.7	40.5	22.2	-15.5	26.9	17.9
Tax Provisions	759	1,027	907	1,188	1,041	1,487	1,114	1,007	3,881	4,650
Net Profit	2,208	3,045	2,602	3,400	2,927	4,234	3,173	2,868	11,255	13,202
Change YoY (%)	21.6	42.5	13.9	27.3	32.5	39.1	21.9	-15.6	26.4	17.3

BSE BUY

CMP INR5,426 | TP: INR6,500 (20%)

EPS CHANGE (%) FY25 | 26: -0.3 | 0.0

- in Dec'24, offsetting the adverse impact of volume decline.
- Transaction revenue to witness growth across cash, derivatives, and MF segments.
- The best ever premium to notional turnover ratio witnessed
 Continued momentum with respect to new listings to boost revenue from service to corporates.
 - Decline in regulatory and clearing costs, due to a fall in notional turnover, to improve profitability.

Quarterly Performance										(INR m)
Y/E March		FY	24			FY2	25E		FY24	FY25E
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE	F124	F123E
Revenue from Operations	2,156	3,145	3,717	4,885	6,077	7,463	7,589	7,635	13,903	28,765
YoY Change (%)	15.4	59.1	82.2	115.2	181.9	137.3	104.2	56.3	70.5	106.9
Total Expenditure	1,455	1,814	2,796	3,923	3,239	3,573	3,385	3,179	9,988	13,376
EBITDA	701	1,331	921	962	2,838	3,890	4,204	4,456	3,915	15,388
Margins (%)	32.5	42.3	24.8	19.7	46.7	52.1	55.4	58.4	28.2	53.5
Depreciation	214	227	249	265	240	291	285	306	954	1,122
Interest	65	0	0	0	0	0	0	0	65	0
Investment Income	556	525	598	600	666	727	675	600	2,279	2,668
PBT before EO Expense	977	1,629	1,271	1,297	3,265	4,325	4,594	4,750	5,174	16,934
Exceptional items	3,657	0	-16	-17	0	-2	0	0	3,624	-2
PBT	4,634	1,629	1,255	1,280	3,265	4,323	4,594	4,750	8,798	16,932
Tax	371	636	371	470	851	1,109	1,148	1,188	1,848	4,296
Rate (%)	8	39	30	37	26	26	25	25	21	25
P/L of Asso. Cos.	119	190	165	244	227	244	245	254	719	970
Reported PAT	4,382	1,184	1,049	1,054	2,642	3,458	3,690	3,816	7,668	13,606
Adj PAT	1,018	1,184	1,060	1,064	2,642	3,459	3,690	3,816	4,326	13,607
YoY Change (%)	995	303	379	19	-40	192	252	262	273	77
Margins (%)	47.2	37.6	28.5	21.8	43.5	46.3	48.6	50.0	55.2	47.3

MCX Neutral

CMP INR6,285 | TP: INR 7,200(+15%)

EPS CHANGE (%): FY25 | 26: -3.7 | 0.0

volatility in commodity prices.

■ Growth momentum maintained for volumes driven by high■ Futures ADTO rose sequentially to INR280b from INR270b in 1QFY25.

INR1.94t in 1QFY25.

Options ADTO increased sequentially to INR2.04t from Costs are expected to remain stable, while revenue growth will drive margin improvement and profitability.

Quarterly Performance (INR m)

		FY	24			FY2	FY24	FY25E		
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE	FYZ4	FYZSE
Sales	1,458	1,651	1,915	1,811	2,344	2,856	3,180	3,337	6,835	11,717
Y-o-Y Gr. (%)	34.0	29.6	33.4	35.4	60.8	73.0	66.1	84.3	33.1	71.4
EBITDA	107	-287	-197	1,020	1,326	1,794	2,036	2,129	643	7,284
Tax	58	16	-91	205	273	374	432	627	189	1,706
Rate (%)	21.6	-9.9	68.3	19.3	19.8	19.6	20.0	27.1	18.2	22.0
Profit from Associate	-13	-10	-11	19	4	4	0	11	-15	19
PAT	197	-191	-54	878	1,109	1,536	1,728	1,694	831	6,068
Y-o-Y Gr. (%)	-53	-130	-114	1,512	464	-906	-3,330	93	-44	630
EPS (INR)	3.9	-3.7	-1.1	17.3	21.8	30.2	34.0	33.3	16.3	119.0
Total Volumes (INR t)	51.8	67.0	73.6	82.7	112.3	143.2	148.4	159.9	275.0	563.7
Y-o-Y Gr. (%)	80.7	86.3	80.6	97.1	116.8	113.8	101.6	93.4	86.7	105.0

CDSL Neutral

CMP INR1,809 | TP: INR1,900 (+5%)

EPS CHANGE (%): FY25 | 26: -1.8 | -1.8

Weak cash delivery volumes and demat addition to hit revenue. This will be offset by recurring annual issuer charges and sustained IPO momentum.

Cost structure expected to remain largely stable.

Quarterly Performance										(INR m)
Y/E March		FY2	4			FY2	!5		FY24	FY25E
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE	F124	FTZSE
Revenue from Operations	1,497	2,073	2,145	2,408	2,574	3,223	3,086	3,369	8,122	12,252
Change YoY (%)	6.8	39.2	51.9	93.0	72.0	55.4	43.9	39.9	46.3	50.8
Employee expenses	226	224	237	276	267	314	314	319	963	1,215
Other Expenses	464	555	593	653	762	910	886	984	2265	3,541
Total Operating Expenses	690	779	830	929	1,029	1,225	1,200	1,302	3,229	4,756
Change YoY (%)	7	39	48	68	49	57	45	40	39.3	47
EBITDA	807	1,294	1,314	1,479	1,544	1,998	1,886	2,067	4,894	7,495
Other Income	242	228	215	266	295	362	380	314	950	1,352
Depreciation	58	65	69	80	98	119	122	123	272	462
PBT	990	1,457	1,460	1,665	1,741	2,241	2,144	2,258	5,572	8,385
Change YoY (%)	28	33	46	100	76	54	47	36	50.7	50
Tax Provisions	242	358	375	390	405	627	536	587	1,365	2,155
P&L from associate	-11	-9	-10	20	5	6	6	6	-11	23
Net Profit	737	1,090	1,075	1,294	1,342	1,620	1,614	1,677	4,197	6,253
Change YoY (%)	28	35	44	105	82	49	50	30	52.0	49

CAMS Buy

CMP INR5,108 | TP: INR6,000 (+17%)

EPS CHANGE (%): FY25 | 26: +0.0 | +0.0

- Stable momentum with respect to equity flows during the quarter will drive revenue growth.
- Operational efficiency is likely to improve profitability.
- Yields are expected to remain stable sequentially as share of equity AUM is maintained.
- The contribution from non-MF businesses will be closely tracked, especially AIF/PMS RTA and Insurance Repository.

Quarterly Performance										(INR m)
Y/E March		FY	24			FY2	5E		FY24	FY25E
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE	F124	F1Z3E
Revenue from Operations	2,613	2,751	2,897	3,105	3,314	3,652	3,725	3,848	11,365	14,538
Change YoY (%)	10.4	13.5	18.9	24.6	26.8	32.7	28.6	23.9	16.9	27.9
Employee Expenses	950	977	997	1,048	1,130	1,186	1,209	1,241	3,972	4,766
Total Operating Expenses	1,512	1,530	1,603	1,671	1,816	1,950	1,981	2,021	6,316	7,767
Change YoY (%)	9.0	12.2	18.4	19.2	20.1	27.5	23.6	20.9	14.7	23.0
EBITDA	1,101	1,221	1,294	1,433	1,498	1,702	1,744	1,827	5,049	6,771
Other Income	97	96	99	114	117	126	135	144	406	522
Depreciation	165	174	185	181	170	184	184	185	705	722
Finance Cost	20	20	21	21	21	22	22	23	82	88
PBT	1,012	1,124	1,187	1,346	1,424	1,622	1,673	1,763	4,668	6,483
Change YoY (%)	16.4	15.9	21.4	36.6	40.7	44.4	41.0	31.0	22.8	38.9
Tax Provisions	255	286	302	316	354	414	418	434	1,159	1,621
Net Profit	757	838	885	1,030	1,070	1,208	1,255	1,329	3,510	4,862
Change YoY (%)	17.1	16.2	20.3	38.5	41.3	44.2	41.8	29.1	23.3	38.5

Kfintech Neutral

CMP INR1,545 | TP: INR1,400 (-9%)

EPS CHANGE (%): FY25 | 26: +0.0 | +0.0

- Strong equity flows during the quarter will drive AUM and revenue growth.
- Contribution from non-MF businesses, especially issuer solutions, to further boost revenue growth.
- Operational efficiency is expected to improve profitability.

Quarterly Performance										(INR m)
Y/E March		FY2	4			FY2	5		FY24	FY25E
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE	F124	FTZJE
Revenue from Operations	1,815	2,090	2,187	2,283	2,376	2,805	2,945	3,088	8,375	11,214
Change YoY (%)	7.6	16.0	16.3	24.7	30.9	34.2	34.7	35.2	16.3	33.9
Employee expenses	756	760	831	850	958	1,018	1,060	1,088	3,197	4,124
Other Expenses	355	393	377	387	421	522	533	552	1,513	2,027
Total Operating Expenses	1,111	1,153	1,208	1,237	1,379	1,539	1,593	1,639	4,709	6,151
Change YoY (%)	4.6	5.7	4.8	2.4	11.4	11.6	3.5	2.9		
EBITDA	704	937	979	1,046	997	1,265	1,352	1,449	3,666	5,063
Other Income	53	63	64	66	81	105	105	115	247	407
Depreciation	124	126	134	146	148	165	169	175	530	657
Finance Cost	29	32	12	11	12	11	11	13	84	46
PBT	604	842	898	955	918	1,195	1,277	1,376	3,298	4,766
Change YoY (%)	18.0	41.5	6.6	6.4	-3.8	30.1	6.9	7.8	27.7	44.5
Tax Provisions	165	223	226	199	237	301	319	343	813	1,201
Net Profit	434	614	668	745	681	893	958	1,033	2,461	3,565
Change YoY (%)	15.9	28.1	25.2	30.6	56.9	45.5	43.3	38.7	25.7	44.9

HDFC Life Buy

CMP: INR617 | TP: INR800(30%)

VNB CHANGE (%): FY25 | 26: +0.9 | +1.0

- New business premium to maintain growth momentum, driven by the Annuity and Par segments.
- VNB margins are likely to expand QoQ with robust VNB growth
- Improvement in persistency ratio and commentary on growth outlook are the key monitorables.
- The share of HDFC Bank in the distribution mix and the outlook ahead will be critical monitorables.

Quarterly Performance										(INR b)
Policy Holder's A/c		FY2	24			FY	25		FY24	FY25E
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE	F124	FTZSE
First Year Premium	18.5	25.7	26.8	40.1	23.6	32.5	34.5	46.8	111.1	138.0
Growth (%)	8.4%	5.9%	-1.7%	-10.1%	27.4%	26.8%	28.7%	16.5%	-1.9%	24.2%
Renewal Premium	58.0	78.4	84.0	114.1	64.1	88.3	99.6	135.0	334.5	398.3
Growth (%)	13.8%	13.5%	16.8%	23.3%	10.5%	12.7%	18.6%	18.4%	17.6%	19.1%
Single Premium	40.2	45.4	44.5	55.2	40.4	48.4	48.1	57.7	185.2	192.3
Growth (%)	24.0%	14.7%	-4.6%	-6.6%	0.6%	6.8%	8.0%	4.5%	4.3%	3.8%
Gross Premium Inc.	116.7	149.4	155.3	209.4	128.1	169.3	182.1	239.5	630.8	728.6
Growth (%)	16.2%	12.5%	6.5%	6.7%	9.7%	13.3%	17.3%	14.4%	9.6%	15.5%
Surplus/(Deficit)	2.1	2.3	0.6	2.7	5.6	5.1	2.3	2.5	7.8	15.6
Growth (%)	0.9%	-7.2%	-81.4%	-52.3%	165.7%	122.6%	282.1%	-6.9%	-43%	101.4%
PAT	4.2	3.8	3.7	4.1	4.8	4.3	4.3	4.8	15.7	18.1
Growth (%)	15.4%	15.5%	15.8%	14.6%	15.0%	14.9%	18.8%	16.8%	15.3%	15.2%
Key Metrics (INRb)										
New Business APE	23.3	30.5	31.9	47.3	28.7	38.6	38.7	55.2	129.6	161.2
Growth (%)	12.8	6.8	-2.1	-8.4	23.1	26.7	21.2	16.7	-1.0%	24.3%
VNB	6.1	8.0	8.6	12.3	7.2	9.4	9.7	14.1	35.0	40.3
Growth (%)	17.8	4.0	-2.2	-18.3	17.7	17.1	13.0	14.0	-4.7%	15.1%
AUM (INR b)	2,533	2,649	2,797	2,922	3,102	3,249	3,396	3,631	2,922	3,631
Growth (%)	18.7	17.8	19.6	22.4	22.5	22.7	21.4	24.2	22.4%	24.2%
Key Ratios (%)										
VNB Margins (%)	26.2	26.2	26.8	26.1	25.0	24.3	25.0	25.5	26.3	25.0

ICICI Prudential Life

Buy

CMP: INR661 | TP: INR840 (27%)

- New business premium is likely to experience strong YoY growth driven by the group business.
- VNB growth is likely to remain healthy, but margin to dip QoQ owing to the higher share of ULIPs.
- VNB CHANGE (%): FY25 | 26: -4.0 | +5.5
- Expense ratio outlook will be the key monitorable.
 - Growth in the Non-Linked business is expected to remain healthy and recovery is projected in the Protection business.

Quarterly Performance										(INR b)
Policy Holder's A/c		FΥ	/24			FY2	25E		EV24	EVALE
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE	FY24	FY25E
First Year Premium	10.2	15.3	15.3	29.5	15.2	20.6	32.9	31.0	70.3	99.8
Growth (%)	-1.5%	5.9%	11.3%	11.9%	48.8%	34.6%	114.7%	5.4%	8.3%	41.9%
Renewal Premium	41.6	58.9	60.8	84.3	43.3	69.9	68.2	91.5	245.6	273.0
Growth (%)	6.8%	4.4%	5.7%	16.6%	4.3%	18.6%	12.3%	8.6%	9.0%	11.2%
Single Premium	21.9	30.1	26.7	37.8	24.3	30.3	32.4	42.6	116.5	129.6
Growth (%)	-5.9%	7.0%	0.9%	20.7%	10.6%	0.9%	21.2%	12.9%	6.7%	11.3%
Gross Premium Income	73.7	104.3	102.8	151.5	82.8	120.8	133.6	165.2	432.4	502.3
Growth (%)	1.5%	5.4%	5.2%	16.6%	12.3%	15.8%	29.9%	9.0%	8.3%	16.2%
PAT	2.1	2.4	2.3	1.7	2.3	2.5	2.5	2.9	8.5	10.2
Growth (%)	32.9%	22.4%	3.1%	-26.0%	8.9%	3.1%	12.0%	65.4%	5.1%	19.6%
Key Metrics (INRb)										
New Business APE	14.6	20.6	19.1	36.2	19.6	25.0	26.0	37.6	90.5	108.2
Growth (%)	-3.9%	3.2%	4.7%	9.6%	34.4%	21.4%	36.2%	3.9%	4.7%	19.6%
VNB	4.4	5.8	4.4	7.8	4.7	5.9	6.0	8.8	22.3	25.3
Growth (%)	-7.0%	-7.1%	-29.4%	-26.4%	7.8%	1.6%	37.0%	13.0%	-19.5%	13.7%
AUM	2,664	2,719	2,867	2,942	3,089	3,205	3,349	3,512	2,942	3,512
Growth (%)	15.8%	11.3%	13.8%	17.1%	15.9%	17.9%	16.8%	19.4%	17.1%	19.4%
Key Ratios (%)										
VNB Margins (%)	30.0	28.0	22.9	21.5	24.0	23.4	23.0	23.3	24.6	23.4

Max Financial Neutral

CMP: INR1101 | TP: INR1200 (+7%)

VNB CHANGE (%): FY25 | 26: -1.5 | +0.1

- New business premium growth sustained in double digits.
- VNB and VNB margin are projected to decline slightly on a sequential basis.
- The proprietary channel is likely to exhibit healthy trends.
- Wallet share with Axis Bank and other bank partners is a key monitorable.

Pallacitation A (a (IND Is)						FY24	FY25E			
Policy Holder's A/c (INR b)	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE		
First Year Premium	9.9	15.3	17.6	25.4	12.6	20.5	21.3	30.9	68.9	85.3
Growth (%)	8.0%	37.7%	20.7%	5.3%	27.1%	33.6%	21.2%	21.9%	16.8%	23.9%
Renewal Premium	30.1	42.0	46.1	66.8	33.2	47.2	53.2	75.4	185.1	212.9
Growth (%)	15.1%	7.5%	14.6%	14.6%	10.3%	12.4%	15.5%	12.8%	13.0%	15.0%
Single Premium	8.7	8.9	9.3	15.2	8.2	9.7	10.1	16.6	41.3	45.9
Growth (%)	52.8%	14.2%	15.5%	66.5%	-5.7%	8.4%	8.7%	9.8%	35.1%	11.0%
Gross Premium Income	48.7	66.3	73.0	107.4	54.0	77.4	84.7	122.9	295.3	344.2
Growth (%)	18.7%	14.2%	16.1%	17.3%	10.8%	16.8%	16.0%	14.5%	16.5%	16.5%
PAT	1.0	1.6	1.5	-0.5	1.6	1.4	1.6	1.8	3.6	6.3
Growth (%)	13.2%	196.2%	-34.9%	-186.4%	51.4%	-11.2%	4.1%	-445.5%	-17.8%	74.8%
Key Metrics (INRb)										
New Business APE	11.1	16.5	18.0	28.7	14.5	21.7	20.7	33.1	73.0	89.9
Growth (%)	10.3%	38.8%	18.9%	13.2%	30.5%	31.3%	15.2%	15.4%	17.7%	23.2%
VNB	2.5	4.2	4.9	8.2	2.5	5.1	4.9	8.2	19.7	20.7
Growth (%)	16.0%	11.5%	-17.5%	6.6%	2.8%	23.1%	-0.6%	-0.6%	1.2%	4.8%
AUM	1,291.3	1,341.6	1,426.2	1,508.4	1,611.5	1,701.4	1,769.5	1,692.7	1,508.4	1,692.7
Growth (%)	20.5%	18.4%	20.5%	22.8%	24.8%	26.8%	24.1%	12.2%	22.8%	12.2%
Key Ratios (%)										
VNB Margins (%)	22.2	25.2	27.2	28.6	17.5	23.6	23.5	24.6	31.2	23.0

SBI Life

CMP: INR1,401 | TP: INR1,850 (+32%)

VNB CHANGE (%): FY25 | 26: -2.1 | -2.1

- Growth in the new business premium is expected to remain
 Cost leadership is projected to continue. stable.

- Single-digit VNB growth is anticipated, while margin is likely
 Sluggish growth in the SBI channel has been an area of to remain flattish QoQ. concern, making the outlook in this area crucial.

Quarterly Performance										(INR b)
Dell'es Heldesle A./e		FY2	4			FY	25		E)/2.4	EVALE
Policy Holder's A/c	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE	FY24	FY25E
First Year Premium	26.4	46.3	56.8	45.3	31.5	49.2	64.6	52.7	174.8	195.8
Growth (%)	3%	33%	12%	11%	19%	6%	14%	16%	15%	12%
Renewal Premium	73.5	101.2	127.2	130.0	85.4	117.2	143.4	151.9	431.9	494.4
Growth (%)	28%	11%	17%	9%	16%	16%	13%	17%	14%	14%
Single Premium	35.7	54.2	40.6	77.1	38.9	37.8	51.0	81.7	207.6	231.8
Growth (%)	18%	35%	21%	93%	9%	-30%	26%	6%	44%	12%
Gross Premium Income	135.6	201.8	224.6	252.4	155.7	204.1	259.0	286.3	814.3	922.0
Growth (%)	19%	21%	16%	26%	15%	1%	15%	13%	21%	13%
PAT	3.8	3.8	3.2	8.1	5.2	5.3	5.0	9.6	18.9	25.1
Growth (%)	45%	1%	6%	4%	36%	39%	56%	19%	10%	33%
Key Metrics (INRb)										
New Business APE	30.3	52.3	61.3	53.3	36.4	53.9	66.3	60.8	197.5	220.8
Growth (%)	4%	33%	13%	17%	20%	3%	8%	14%	17%	12%
VNB	8.7	14.9	16.8	15.1	9.7	14.5	17.9	16.4	55.5	58.5
Growth (%)	-1%	20%	11%	5%	11%	-3%	6%	9%	9%	5%
AUM	3,283	3,452	3,714	3,889	4,148	4,390	4,565	4,603	3,889	4,603
Growth (%)	25%	22%	24%	27%	26%	27%	23%	18%	27%	18%
Key Ratios (%)										
VNB Margins (%)	28.8	28.5	27.4	28.3	26.8	26.9	27.0	27.0	28.1	26.5

ICICI Lombard

CMP INR1,808 | TP: INR2,200 (+22%)

improvement expected on a QoQ basis.

EPS CHANGE (%) FY25 | 26: -1.6 | -6.7

- Slowdown in motor segment and change in accounting for long-term health policies hurt premium growth.
- Change in accounting in the health segment (for long-term policies) will result in elevated expense ratios. Claims environment to remain stable YoY and loss ratio

Quarterly Performance										(INRb)
Y/E March	FY24 FY25E									FY25E
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE	FY24	FTZSE
Net Earned Premium	38.9	43.1	43.0	43.7	45.0	50.3	48.7	49.4	168.7	193.4
Total Income	45.4	50.5	50.0	51.6	53.5	58.5	57.6	58.5	197.5	228.2
Change YoY (%)	14.1	12.2	14.7	-1.8	17.9	15.9	15.1	13.4	9.2	15.5
Incurred Claims	28.8	30.5	30.1	30.0	33.3	35.9	34.1	34.3	119.4	137.6
Total Operating Expenses	42.1	44.5	45.9	46.0	48.5	51.9	51.4	52.3	178.5	204.1
Change YoY (%)	14.9	11.6	12.3	15.7	15.3	16.5	12.0	13.8	13.6	14.3
Underwriting Profit	-3.2	-1.5	-2.8	-2.3	-3.5	-1.6	-2.6	-3.0	-9.8	-10.7
Rep Net Profit	3.9	5.8	4.3	5.2	5.8	6.9	6.3	5.6	19.2	24.6
Claims Ratio	74.1	70.7	70.0	68.6	74.0	71.4	70.0	69.4	70.8	71.1
Commission Ratio	12.5	17.4	18.0	19.9	15.0	17.5	18.7	19.0	17.0	17.5

Star Health Buy

13.7

102.2

13.3

102.3

15.6

104.5

CMP INR482 | TP: INR560 (+16%)

Expense Ratio

Combined Ratio

EPS CHANGE (%): FY25 | 26: -18.0 | -13.6

15.5

103.3

15.3

104.0

16.5

104.9

Premium expected to grow in double digits, but to be impacted by change in accounting for long-term policies

17.2

103.8

15.8

103.9

15.5

103.6

- Claims ratio anticipated to improve sequentially.
- Change in accounting in the health segment (for long-term policies) will result in elevated expense ratios.

16.0

104.7

Quarterly Performance										(INRm)
Y/E March		EV24	FY25E							
	1Q	2Q	3Q	4Q	1Q	2Q	3QE	4QE	FY24	FTZSE
Net Earned Premium	30,438	32,056	32,936	33,953	35,203	37,039	37,936	39,517	1,29,383	1,49,695
Total Income	31,898	33,566	34,563	35,764	36,916	39,142	40,036	41,989	1,35,790	1,58,083
Change YoY (%)	13.6	15.0	15.9	17.1	15.7	16.6	15.8	17.4	15.4	16.4
Incurred Claims	19,909	22,022	22,295	21,774	23,789	26,959	26,935	26,356	85,999	1,04,038
Total Operating Expenses	28,983	32,839	31,794	34,864	33,800	38,986	38,500	41,387	1,28,480	1,52,672
Change YoY (%)	14.5	17.0	16.0	17.1	16.6	18.7	21.1	18.7	16.2	18.8
Underwriting Profit	1,454	-784	1,142	-911	1,404	-1,947	-564	-1,870	903	-2,977
Net Profit	2,879	1,253	2,896	1,423	3,189	1,113	2,178	1,697	8,450	8,178
Claims Ratio	65.4	68.7	67.7	64.1	67.6	72.8	71.0	66.7	66.5	69.5
Commission Ratio	13.1	13.7	11.1	14.3	13.5	13.8	13.8	14.0	13.2	13.8
Expense Ratio	19.3	16.8	19.0	14.4	18.1	16.4	17.6	15.0	17.0	16.6
Combined Ratio	97.8	99.2	97.8	92.8	99.2	103.0	102.4	95.7	96.7	99.9

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

NOTES

MOTILAL OSWAL

Explanation of Investment Rating		
Investment Rating	Expected return (over 12-month)	
BUY	>=15%	
SELL	<-10%	
NEUTRAL	> - 10 % to 15%	
UNDER REVIEW	Rating may undergo a change	
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation	

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures:

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL),NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at http://onlinereports.moti wal.com/Dormant/documents/Associate%20Details.pdf

Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx

MOFSL, it's associates, Research Analyst or their relatives may have any financial interest in the subject company. MOFSL and/or its associates and/or Research Analyst or their relatives may have actual beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance. MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may have any other potential conflict of interests at the time of publication of the research report or at the time of public appearance, however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

In the past 12 months, MOFSL or any of its associates may have:

- received any compensation/other benefits from the subject company of this report
- managed or co-managed public offering of securities from subject company of this research report,
- received compensation for investment banking or merchant banking or brokerage services from subject company of this research report, c)
- received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company of this research report. d)
- MOFSL and it's associates have not received any compensation or other benefits from the subject company or third party in connection with the research report.
- Subject Company may have been a client of MOFSL or its associates during twelve months preceding the date of distribution of the research report.
- Research Analyst may have served as director/officer/employee in the subject company.
- MOFSL and research analyst may engage in market making activity for the subject company.

MOFSL and its associate company(ies), and Research Analyst and their relatives from time to time may have: a) a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein.

(b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures. To enhance transparency, MOFSL has incorporated a Disclosure of Interest Statement in this document. This should, however, not be treated as endorsement of the views expressed in the report. MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Dis	closure of Interest Statement	Companies where there is interest
Ana	alyst ownership of the stock	No
٨ ۵	ronk of daily aloaing priess of accurition is	available at www.nooindia.com, www.booindia.com, Doograph Anglyat views on Cubicat Company may very based on Eundamental research and Toolphical

ties is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to subject company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Financial Services Limited (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

MOTILAL Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts), and under

MOTILAL OSWAL

applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com.

Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai-400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No: 022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412 . AMFI: ARN .: 146822. IRDA Corporate Agent – CA0579. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.